Search results
Results from the WOW.Com Content Network
Miglitol is an oral alpha-glucosidase inhibitor used in the treatment of type 2 diabetes. It works by reversibly inhibiting alpha-glucosidase enzymes in the small intestine, which delays the digestion of complex carbohydrates and subsequently reduces postprandial glucose levels. [ 1 ]
Acarbose degradation is the unique feature of glycoside hydrolases in gut microbiota, acarbose degrading glucosidase, which hydrolyze acarbose into an acarviosine-glucose and glucose. [17] Human enzymes do transform acarbose: the pancreatic alpha-amylase is able to perform a rearrangement reaction , moving the glucose unit in the "tail" maltose ...
Therefore, a drug given by the intravenous route will have an absolute bioavailability of 100% (f = 1), whereas drugs given by other routes usually have an absolute bioavailability of less than one. If we compare the two different dosage forms having same active ingredients and compare the two drug bioavailability is called comparative ...
Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal. [ 2 ] There are three major drugs which belong to this class, acarbose , miglitol and voglibose, [ 2 ] of which voglibose is the newest.
The absorption rate constant K a is a value used in pharmacokinetics to describe the rate at which a drug enters into the system. It is expressed in units of time −1. [1] The K a is related to the absorption half-life (t 1/2a) per the following equation: K a = ln(2) / t 1/2a. [1] K a values can typically only be found in research articles. [2]
In contrast to this article's previous definition of the Hill equation, the IUPHAR defines the Hill equation in terms of the tissue response (), as [1] = [] + [] = + ([]) where [] is the drug concentration, is the Hill coefficient, and is the drug concentration that produces a 50% maximal response.
This page was last edited on 2 December 2024, at 21:02 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
Vildagliptin is indicated, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes as monotherapy in people in whom metformin is inappropriate due to contraindications or intolerance; and in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycemic control.